Targeting Parkinson Disease "Pathway Abnormalities" With GT-02287: Jonas Hannestad, MD, PhD

Scroll Top

Targeting Parkinson Disease “Pathway Abnormalities” With GT-02287: Jonas Hannestad, MD, PhD

NeurologyLive

Oct 06, 2025

October 9, 2025

https://pharmaphorum.com/rd/allosteric-small-molecule-therapies-pd-gene-mack

October 8, 2025

https://www.ddw-online.com/early-data-suggest-gt-02287-slows-parkinsons-disease-37433-202510/

October 8, 2025

https://www.clinicaltrialvanguard.com/news/new-parkinsons-drug-gt-02287-shows-promising-phase-1b-data/